<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446679</url>
  </required_header>
  <id_info>
    <org_study_id>LIP003</org_study_id>
    <nct_id>NCT01446679</nct_id>
  </id_info>
  <brief_title>Special Drug Use-Results Survey of Lipitor Tablets</brief_title>
  <acronym>ALWAYS</acronym>
  <official_title>Special Drug Use-Results Survey of Lipitor Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve
      the category-specific targeted lipid levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To confirm the low-density lipoprotein cholesterol (LDL-C)-lowering effect of 24 weeks of
      treatment with LipitorÂ®(Generic Name : atorvastatin calcium) Tablets and determine the rate
      of achievement of the category-specific target LDL-C level in patients with
      hypercholesterolemia; and to confirm the usefulness (efficacy and safety) of atorvastatin in
      patients who have not responded sufficiently to other statin therapies
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma LDL-C concentration</measure>
    <time_frame>0, 4, 12 and 24 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in rate of achievement of the category-specific target LDL-C level</measure>
    <time_frame>0, 4, 12 and 24 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma lipid values (LDL cholesterol, HDL cholesterol, triglycerides, total cholesterol, and malondialdehyde-modified LDL [MDL-LDL])</measure>
    <time_frame>0, 4, 12 and 24 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in renal function test values (urinary albumin, urinary creatinine, urinary protein, and serum creatinine)</measure>
    <time_frame>0, 4, 12 and 24 week</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24050</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>atrovastatin group</arm_group_label>
    <description>Who receive atrovastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atrovastatin</intervention_name>
    <description>oral</description>
    <arm_group_label>atrovastatin group</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypercholesterolemia who have not achieved the category-specific target lipid
        level in other statin therapies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients with hypercholesterolemia who have not achieved the category-specific target lipid
        level
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contract</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Touhoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipitor</keyword>
  <keyword>HMG-CoA reductase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

